Show simple item record

dc.contributor.authorTesileanu, M. S.
dc.contributor.authorSanson, M.
dc.contributor.authorWick, W.
dc.contributor.authorBrandes, A. A.
dc.contributor.authorClement, P. M.
dc.contributor.authorErridge, S. C.
dc.contributor.authorVogelbaum, M. A.
dc.contributor.authorNowak, A. K.
dc.contributor.authorBaurain, J. F.
dc.contributor.authorMason, W. P.
dc.contributor.authorWheeler, H.
dc.contributor.authorChinot, O. L.
dc.contributor.authorGill, S.
dc.contributor.authorGrif, M.
dc.contributor.authorRogers, L.
dc.contributor.authorTaal, W.
dc.contributor.authorRuda, R.
dc.contributor.authorWeller, M.
dc.contributor.authorMcBain, Catharine A
dc.contributor.authorvan Linde, M. E.
dc.contributor.authorAldape, K.
dc.contributor.authorJenkins, R. B.
dc.contributor.authorKros, J. M.
dc.contributor.authorWesseling, P.
dc.contributor.authorvon Deimling, A.
dc.contributor.authorHoogstrate, Y.
dc.contributor.authorde Heer, I.
dc.contributor.authorAtmodimedjo, P. N.
dc.contributor.authorDubbink, H. J.
dc.contributor.authorBrouwer, R. W. W.
dc.contributor.authorIjcken, W.
dc.contributor.authorCheung, K. J.
dc.contributor.authorGolfinopoulos, V.
dc.contributor.authorBaumert, B. G.
dc.contributor.authorGorlia, T.
dc.contributor.authorFrench, P. J.
dc.contributor.authorvan den Bent, M. J.
dc.date.accessioned2022-08-17T09:52:26Z
dc.date.available2022-08-17T09:52:26Z
dc.date.issued2022en
dc.identifier.citationTesileanu MS, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, et al. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical Cancer Research. 2022 Jun;28(12):2527-35. PubMed PMID: WOS:000814512400001. Pubmed Central PMCID: 9297529.en
dc.identifier.pmid35275197en
dc.identifier.doi10.1158/1078-0432.CCR-21-4283.en
dc.identifier.urihttp://hdl.handle.net/10541/625528
dc.description.abstractPurpose: In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase-wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]. Patients and methods: From the randomized phase III CATNON study examining the addition of adjuvant and concurrent temozolomide to radiotherapy in anaplastic astrocytomas, we selected a subgroup of IDH1/2wt and H3F3Awt tumors with presence of TERT promoter mutations and/or EGFR amplifications and/or combined gain of chromosome 7 and loss of chromosome 10. Molecular abnormalities including MGMT promoter methylation status were determined by next-generation sequencing, DNA methylation profiling, and SNaPshot analysis. Results: Of the 751 patients entered in the CATNON study, 670 had fully molecularly characterized tumors. A total of 159 of these tumors met the WHO 2021 molecular criteria for glioblastoma, IDH-wt. Of these patients, 47 received radiotherapy only and 112 received a combination of radiotherapy and temozolomide. There was no added effect of temozolomide on either overall survival [HR, 1.19; 95% confidence interval (CI), 0.82-1.71] or progression-free survival (HR, 0.87; 95% CI, 0.61-1.24). MGMT promoter methylation was prognostic for overall survival, but was not predictive for outcome to temozolomide treatment either with respect to overall survival or progression-free survival. Conclusions: In this cohort of patients with glioblastoma, IDH-wt temozolomide treatment did not add benefit beyond that observed from radiotherapy, regardless of MGMT promoter status. These findings require a new well-powered prospective clinical study to explore the efficacy of temozolomide treatment in this patient population.en
dc.relation.urlhttps://dx.doi.org/10.1158/1078-0432.CCR-21-4283.en
dc.titleTemozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post hoc analysis of the eortc randomized phase III CATNON trialen
dc.typeArticleen
dc.contributor.departmentNeurology Department, Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlandsen
dc.identifier.journalClinical Cancer Researchen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record